Refine
Document Type
- Article (6)
- Doctoral Thesis (1)
Has Fulltext
- yes (7)
Is part of the Bibliography
- no (7)
Keywords
- - (5)
- CRISPR/Cas9 (2)
- Cerebral cavernous malformations (2)
- blood outgrowth endothelial cells (2)
- cerebral cavernous malformation (2)
- Angiogenese (1)
- Angiogenesis (1)
- Animal models (1)
- CCM1 (1)
- CNV analyses (1)
Institute
Publisher
- Frontiers Media S.A. (2)
- S. Karger AG (2)
- AIP Publishing (1)
- Wiley (1)
Mechanical properties have been proven to be a pivotal parameter to enhance our understanding of living systems. While research during the last decades focused on cells and tissues, little is known about the role of organelle mechanics in cell function. Here, mitochondria are of specific interest due to their involvement in numerous physiological and pathological processes, e.g., in the production and homeostasis of reactive oxygen species (ROS). Using real-time fluorescence and deformability cytometry, we present a microfluidic technology that is capable to determine the mechanical properties of individual mitochondria at a throughput exceeding 100 organelles per second. Our data on several thousands of viable mitochondria isolated from rat C6 glial cells yield a homogenous population with a median deformation that scales with the applied hydrodynamic stress. In two proof-of-principle studies, we investigated the impact of exogenously and endogenously produced ROS on mitochondria mechanics. Exposing C6 cells to hydrogen peroxide (H2O2) triggers superoxide production and leads to a reduction in mitochondria size while deformation is increased. In a second study, we focused on the knockout of tafazzin, which has been associated with impaired remodeling of the mitochondrial membrane and elevated levels of ROS. Interestingly, our results reveal the same mechanical alterations as observed after the exposure to H2O2, which points to a unified biophysical mechanism of how mitochondria respond to the presence of oxidative stress. In summary, we introduce high-throughput mechanical phenotyping into the field of organelle biology with potential applications for understanding sub-cellular dynamics that have not been accessible before.
Cerebral cavernous malformations are slow-flow thrombi-containing vessels induced by two-step inactivation of the CCM1, CCM2 or CCM3 gene within endothelial cells. They predispose to intracerebral bleedings and focal neurological deficits. Our understanding of the cellular and molecular mechanisms that trigger endothelial dysfunction in cavernous malformations is still incomplete. To model both, hereditary and sporadic CCM disease, blood outgrowth endothelial cells (BOECs) with a heterozygous CCM1 germline mutation and immortalized wild-type human umbilical vein endothelial cells were subjected to CRISPR/Cas9-mediated CCM1 gene disruption. CCM1
−/− BOECs demonstrated alterations in cell morphology, actin cytoskeleton dynamics, tube formation, and expression of the transcription factors KLF2 and KLF4. Furthermore, high VWF immunoreactivity was observed in CCM1
−/−
BOECs, in immortalized umbilical vein endothelial cells upon CRISPR/Cas9-induced inactivation of either CCM1, CCM2 or CCM3 as well as in CCM tissue samples of familial cases. Observer-independent high-content imaging revealed a striking reduction of perinuclear Weibel-Palade bodies in unstimulated CCM1
−/−
BOECs which was observed in CCM1
+/− BOECs only after stimulation with PMA or histamine. Our results demonstrate that CRISPR/Cas9 genome editing is a powerful tool to model different aspects of CCM disease in vitro and that CCM1 inactivation induces high-level expression of VWF and redistribution of Weibel-Palade bodies within endothelial cells.
Abstract
Background
The CRISPR/Cas9 system has opened new perspectives to study the molecular basis of cerebral cavernous malformations (CCMs) in personalized disease models. However, precise genome editing in endothelial and other hard‐to‐transfect cells remains challenging.
Methods
In a proof‐of‐principle study, we first isolated blood outgrowth endothelial cells (BOECs) from a CCM1 mutation carrier with multiple CCMs. In a CRISPR/Cas9 gene correction approach, a high‐fidelity Cas9 variant was then transfected into patient‐derived BOECs using a ribonucleoprotein complex and a single‐strand DNA oligonucleotide. In addition, patient‐specific CCM1 knockout clones were expanded after CRISPR/Cas9 gene inactivation.
Results
Deep sequencing demonstrated correction of the mutant allele in nearly 33% of all cells whereas no CRISPR/Cas9‐induced mutations in predicted off‐target loci were identified. Corrected BOECs could be cultured in cell mixtures but demonstrated impaired clonal survival. In contrast, CCM1‐deficient BOECs displayed increased resistance to stress‐induced apoptotic cell death and could be clonally expanded to high passages. When cultured together, CCM1‐deficient BOECs largely replaced corrected as well as heterozygous BOECs.
Conclusion
We here demonstrate that a non‐viral CRISPR/Cas9 approach can not only be used for gene knockout but also for precise gene correction in hard‐to‐transfect endothelial cells (ECs). Comparing patient‐derived isogenic CCM1+/+, CCM1+/−, and CCM1−/− ECs, we show that the inactivation of the second allele results in clonal evolution of ECs lacking CCM1 which likely reflects the initiation phase of CCM genesis.
Autosomal dominant cerebral cavernous malformation (CCM) represents a genetic disorder with a high mutation detection rate given that stringent inclusion criteria are used and copy number variation analyses are part of the diagnostic workflow. Pathogenic variants in either CCM1 (KRIT1), CCM2 or CCM3 (PDCD10) can be identified in 87–98% of CCM families with at least two affected individuals. However, the interpretation of novel sequence variants in the 5′-region of CCM2 remains challenging as there are various alternatively spliced transcripts and different transcription start sites. Comprehensive genetic and clinical data of CCM2 patients with variants in cassette exons that are either skipped or included into alternative CCM2 transcripts in the splicing process can significantly facilitate clinical variant interpretation. We here report novel pathogenic CCM2 variants in exon 3 and the adjacent donor splice site, describe the natural history of CCM disease in mutation carriers and provide further evidence for the classification of the amino acids encoded by the nucleotides of this cassette exon as a critical region within CCM2. Finally, we illustrate the advantage of a combined single nucleotide and copy number variation detection approach in NGS-based CCM1/CCM2/CCM3 gene panel analyses which can significantly reduce diagnostic turnaround time.
Based on the latest gnomAD dataset, the prevalence of symptomatic hereditary cerebral cavernous malformations (CCMs) prone to cause epileptic seizures and stroke-like symptoms was re-evaluated in this review and calculated to be 1:5,400-1:6,200. Furthermore, state-of-the-art molecular genetic analyses of the known CCM loci are described which reach an almost 100% mutation detection rate for familial CCMs if whole genome sequencing is performed for seemingly mutation-negative families. An update on the spectrum of CCM1, CCM2, and CCM3 mutations demonstrates that deep-intronic mutations and submicroscopic copy-number neutral genomic rearrangements are rare. Finally, this review points to current guidelines on genetic counselling, neuroimaging, medical as well as neurosurgical treatment and highlights the formation of active patient organizations in various countries.
Cerebral cavernous malformations (CCMs) are prevalent slow-flow vascular lesions which harbour the risk to develop intracranial haemorrhages, focal neurological deficits, and epileptic seizures. Autosomal dominantly inherited CCMs were found to be associated with heterozygous inactivating mutations in 3 genes, CCM1(KRIT1), CCM2(MGC4607), and CCM3(PDCD10) in 1999, 2003 and 2005, respectively. Despite the availability of high-throughput sequencing techniques, no further CCM gene has been published since. Here, we report on the identification of an autosomal dominantly inherited frameshift mutation in a gene of thus far unknown function, FAM222B(C17orf63), through exome sequencing of CCM patients mutation-negative for CCM1-3. A yeast 2-hybrid screen revealed interactions of FAM222B with the tubulin cytoskeleton and STAMBP which is known to be associated with microcephaly-capillary malformation syndrome. However, a phenotype similar to existing models was not found, neither in fam222bb/fam222ba double mutant zebrafish generated by transcription activator-like effector nucleases nor in an in vitro sprouting assay using human umbilical vein endothelial cells transfected with siRNA against FAM222B. These observations led to the assumption that aberrant FAM222B is not involved in the formation of CCMs.
Zerebrale kavernöse Malformationen sind Gefäßfehlbildungen des menschlichen zentralen Nervensystems, die mit einer Prävalenz von etwa 1:650 in der Bevölkerung auftreten und zu rezidivierenden Kopfschmerzen, Krampfanfällen und Gehirnblutungen führen können. Diese Läsionen treten sowohl sporadisch als auch als Konsequenz von erblichen Mutationen (familiäre Kavernomatose) mit unvollständiger Penetranz und variabler Expressivität auf. Kausale Mutationen sind für die Gene CCM1 ( KRIT1), CCM2 (Malcavernin) und CCM3 (PDCD10) beschrieben. Die vorliegende Dissertationsarbeit mit dem Titel „Identifizierung und Charakterisierung eines neuen Kandidatengens für kavernöse Gefäßmalformationen des zentralen Nervensystems“ hatte die Suche neuer CCM-assoziierter Gene und deren Beschreibung zur Aufgabe. Als Ausgangspunkt dienten fünf Indexpatienten aus der Kohorte Stahl et al. 2008, bei denen keine ursächliche Mutation in den bekannten CCM-Genen identifiziert werden konnte. Die Exomsequenzierung mittels SOLiD™ 5500XL ergab für die vier isolierten und den familiären Fall mehr als 210.000 Varianten. Nach Filterung und Priorisierung dieser Veränderungen wurden acht Kandidatengene definiert, von denen fünf mittels klassischer Sanger-Sequenzierung validiert werden konnten. Das vielversprechendste Kandidatengen, FAM222B (C17orf63), in dem 2012 keine Loss-of-function Mutationen bekannt waren und das für ein Protein unbekannter Struktur und Funktion kodiert, wurde für die weitere Charakterisierung ausgewählt. Zunächst konnten durch einen Yeast Two-Hybrid Screen Interaktionspartner identifiziert werden, die sich in die bekannten CCM-Signalwege integrieren ließen. Funktionelle Studien mittels Morpholino- und TALEN-Technik im Zebrafischmodell und mit humanen Nabelschnurvenenendothelzellen zeigten jedoch keinen signifikanten Effekt von FAM222B auf die Angiogenese. Auch eine detaillierte Bewertung der Informationen, die erst Ende 2014 in der ExAC-Datenbank veröffentlicht wurden, spricht in Zusammenschau mit den experimentellen Daten eher dagegen, FAM222B als neues Kandidatengen für die Entstehung von CCMs einzustufen. Parallel zu den funktionellen Studien wurde die Kohorte von Stahl et al. 2008 kontinuierlich erweitert. Bei den molekulargenetischen Analysen fanden sich mehr kausale Mutationen im CCM3-Gen als bisher angenommen. Ferner konnte gezeigt werden, dass rund ein Drittel der Probanden vor Erreichen des Erwachsenenalters und ein Fünftel der Mutationsträger bereits vor dem 10. Lebensjahr erkranken.